ADC Therapeutics

71 articles with ADC Therapeutics

• ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

  10/9/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the underwriters in its recent upsized public offering of 6,000,000 common shares, which closed on September 28, 2020, have exercised in full

• New Ventures Funds Rebrands as Scientia Ventures

  10/2/2020

  New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.

• ADC Therapeutics Announces Pricing of Public Offering

  9/24/2020

  ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the pricing of an upsized public offering of 6,000,000 shares of its common shares at a price of $34.00 per share.

• ADC Therapeutics Announces Proposed Public Offering

  9/21/2020

  ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the commencement of a proposed underwritten public offering of 5,500,000 shares of its common shares. Certain existing shareholders expect t

• ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

  9/21/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the submission of a Biologics License Application (B

• ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020

  9/17/2020

  Preliminary pharmacokinetic and biomarker data support continued evaluation of Cami as a novel immuno-oncology approach for patients with solid tumor cancers LAUSANNE, Switzerland--( BUSINESS WIRE )-- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies

• ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers

  9/10/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hem

• ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131

  9/5/2020

  ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities, Inc., the lead book-running managers in the Company’s recent initial public offering, are releasing a lock-up restriction with respect to 105,000 common shares held by A.T. Holdings II Sàrl, an affiliate of Peter B. Corr and Stephen Evans-Freke who are members of the Company’s board of directors, as part of a

• ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights

  8/18/2020

  On track to file BLA for Lonca for relapsed or refractory DLBCL later this year with commercial launch preparations ongoing

• ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020

  8/12/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 18, 2020

• Synaffix Announces Expansion of Collaboration with ADC Therapeutics

  7/23/2020

  Synaffix B.V. announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies.

• ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib

  7/17/2020

  Combination is being evaluated in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL)

• ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine

  7/6/2020

  ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the pivotal Phase 2 clinical trial of camidanlumab

• 

  Clinical Catch-Up: June 8-12

  6/15/2020

  It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

• ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

  6/12/2020

  Lonca demonstrated an overall response rate of 48.3% and complete response rate of 24.1% in the pivotal Phase 2 single-agent trial

• 

  European Hematology Association Meeting Kicks Off with Strong Data Presentations

  6/12/2020

  Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.

• ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress

  6/5/2020

  ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it will h

• ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress

  5/21/2020

  Interim results of pivotal Phase 2 trial reinforce potential of Lonca to become a key part of the treatment paradigm for patients with relapsed or refractory diffuse large B-cell lymphoma

• ADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit Facility with Deerfield

  5/19/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today the closing of its initial public offering of 14,082,475 shares

• ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors

  4/27/2020

  ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced the appointment of Victor Sandor, M.D., to its Board of Directors.